A prospective, multicentre, randomised, active-controlled, observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the safety, tolerability and immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects
A prospective, multicentre, randomised, active-controlled, observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the safety, tolerability and immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects